Miriam A M Nji1, Scott D Solomon2, Lin Yee Chen3, Amil M Shah2, Elsayed Z Soliman4, Aniqa B Alam1, Vinita Subramanya1, Alvaro Alonso5. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 2. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. 3. Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. 4. Epidemiological Cardiology Research Center (EPICARE), Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston Salem, NC, USA. 5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. Electronic address: alvaro.alonso@emory.edu.
Abstract
AIMS: To determine the prevalence and incidence of AF among HF subtypes in a biracial community-based cohort. METHODS: We studied 6496 participants in the Atherosclerosis Risk in Community study (mean age, 75.8 ± 5.3, 59% women, 23% black) who attended the 2011-2013 visit. HF was identified from physician adjudicated diagnosis, hospital discharges, and self-report. HF subtypes were based on echocardiography. A left ventricular ejection fraction <40% represents HF with reduced ejection fraction (HFrEF), 40%-49% for HF with midrange ejection fraction (HFmEF), and ≥ 50% for HF with preserved ejection fraction (HFpEF). AF was ascertained through 2017 from study electrocardiograms, hospital discharges, and death certificates. Confounder-adjusted logistic regression and Cox models were used to estimate associations of HF subtype with prevalent and incident AF. RESULTS: Among eligible participants, 393 had HF (HFpEF = 232, HFmEF = 41, HFrEF = 35 and unclassified HF = 85) and 735 had AF. Compared to those without HF, all HF subtypes were more likely to have prevalent AF [odds ratio (95% confidence interval (CI)) 7.4 (5.6-9.9) for HFpEF, 8.1 (4.3-15.3) for HFmEF, 10.0 (5.0-20.2) for HFrEF, 8.8 (5.6-14.0) for unclassified HF]. Among participants without AF at baseline (n = 5761), 610 of them developed AF. Prevalent HF was associated with increased risk of AF [hazard ratio (95%CI) 2.3 (1.6-3.2) for HFpEF, 5.0 (2.7-9.3) for HFmEF, 3.5 (1.7-7.6) for HFrEF, 1.9 (0.9-3.7) for unclassified HF]. CONCLUSION: AF and HF frequently co-occur, with small differences by HF subtype, underscoring the importance of understanding the interplay of these two epidemics and evaluating shared preventive and therapeutic strategies.
AIMS: To determine the prevalence and incidence of AF among HF subtypes in a biracial community-based cohort. METHODS: We studied 6496 participants in the Atherosclerosis Risk in Community study (mean age, 75.8 ± 5.3, 59% women, 23% black) who attended the 2011-2013 visit. HF was identified from physician adjudicated diagnosis, hospital discharges, and self-report. HF subtypes were based on echocardiography. A left ventricular ejection fraction <40% represents HF with reduced ejection fraction (HFrEF), 40%-49% for HF with midrange ejection fraction (HFmEF), and ≥ 50% for HF with preserved ejection fraction (HFpEF). AF was ascertained through 2017 from study electrocardiograms, hospital discharges, and death certificates. Confounder-adjusted logistic regression and Cox models were used to estimate associations of HF subtype with prevalent and incident AF. RESULTS: Among eligible participants, 393 had HF (HFpEF = 232, HFmEF = 41, HFrEF = 35 and unclassified HF = 85) and 735 had AF. Compared to those without HF, all HF subtypes were more likely to have prevalent AF [odds ratio (95% confidence interval (CI)) 7.4 (5.6-9.9) for HFpEF, 8.1 (4.3-15.3) for HFmEF, 10.0 (5.0-20.2) for HFrEF, 8.8 (5.6-14.0) for unclassified HF]. Among participants without AF at baseline (n = 5761), 610 of them developed AF. Prevalent HF was associated with increased risk of AF [hazard ratio (95%CI) 2.3 (1.6-3.2) for HFpEF, 5.0 (2.7-9.3) for HFmEF, 3.5 (1.7-7.6) for HFrEF, 1.9 (0.9-3.7) for unclassified HF]. CONCLUSION: AF and HF frequently co-occur, with small differences by HF subtype, underscoring the importance of understanding the interplay of these two epidemics and evaluating shared preventive and therapeutic strategies.
Authors: Wayne D Rosamond; Patricia P Chang; Chris Baggett; Anna Johnson; Alain G Bertoni; Eyal Shahar; Anita Deswal; Gerardo Heiss; Lloyd E Chambless Journal: Circ Heart Fail Date: 2012-01-23 Impact factor: 8.790
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur J Heart Fail Date: 2016-05-20 Impact factor: 15.534
Authors: Alvaro Alonso; Faye L Lopez; Kunihiro Matsushita; Laura R Loehr; Sunil K Agarwal; Lin Y Chen; Elsayed Z Soliman; Brad C Astor; Josef Coresh Journal: Circulation Date: 2011-06-06 Impact factor: 29.690
Authors: Susan Colilla; Ann Crow; William Petkun; Daniel E Singer; Teresa Simon; Xianchen Liu Journal: Am J Cardiol Date: 2013-07-04 Impact factor: 2.778
Authors: Richard K Cheng; Margueritte Cox; Megan L Neely; Paul A Heidenreich; Deepak L Bhatt; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow Journal: Am Heart J Date: 2014-07-22 Impact factor: 4.749
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray Journal: Circulation Date: 2013-12-17 Impact factor: 29.690